We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Aims to Scale Down Unnecessary IND Safety Reports
FDA Aims to Scale Down Unnecessary IND Safety Reports
December 21, 2012
Final FDA guidance has clarified the agency’s expedited safety reporting requirements for drugs under an IND as the agency works to cut down on unnecessary adverse experience reports.